Lb. Owenschaub et al., ANTI-FAS ON NONHEMATOPOIETIC TUMORS - LEVELS OF FAS APO-1 AND BCL-2 ARE NOT PREDICTIVE OF BIOLOGICAL RESPONSIVENESS/, Cancer research, 54(6), 1994, pp. 1580-1586
Fas/APO-1 is a cell surface protein known to trigger apoptosis in a va
riety of cell types upon specific antibody binding. Although extensive
ly studied on normal and malignant hematopoietic cells, little is know
n about Fas/APO-1 on nonhematopoietic cells. In the study presented he
re, we have examined Fas/APO-1 expression and function on 11 human tum
ors of nonhematopoietic origin. By dow cytometric analysis, Fas/APO-1
was expressed on 10 of the 11 tumors at levels comparable to those pre
viously reported for lymphoid cells sensitive to the cytolytic effects
of anti-Fas. Despite abundant cell surface expression, only 4 of the
10 Fas-positive tumors were sensitive to the cell-killing effects of a
nti-Fas. Moreover, anti-Fas enhanced the growth of 2 of 10 Fas-positiv
e tumors. Additional studies using cycloheximide demonstrated that de
novo protein synthesis was required for anti-Fas-triggered growth stim
ulation and, at least in one case, was responsible for the resistance
to antibody-induced apoptosis. The biological effects initiated by ant
i-Fas engagement, however were not correlated with endogenous bcl-2 ex
pression. This report documents that: (a) Fas/APO-1 is widely expresse
d on cultured nonhematopoietic tumors; (b) the inherent susceptibility
to anti-Fas-induced apoptosis is not correlated with expression of th
e Fas/APO-1 protein; (c) Fas/APO-1 engagement can result in growth enh
ancement; and (d) protective/growth-promoting proteins other than bcl-
2 may contribute to the diverse spectrum of biological effects induced
by anti-Fas engagement of the Fas/APO-1 protein.